DOI: 10.21088/jcms.2454.7123.11225.1

Journal of Cardiovascular Medicine and Surgery
Volume 11 Number 2/May – August 2025

ORIGINAL ARTICLE

Exploring the Hidden Heart: Unveiling the Mysteries of Congenital Heart Disease

Durga Prasad Rath[1], Ajit Pal Singh[2], Rahul Saxena[3], Suyash Saxena[4]

HOW TO CITE THIS ARTICLE:

Durga Prasad Rath, Ajit Pal Singh et al. Exploring the Hidden Heart: Unveiling the Mysteries of Congenital Heart Disease (CHD). Indian J Cardiovasc Med Surg.2025;11(2): 51–62.

ABSTRACT

Background: Congenital heart disease (CHD) is the most prevalent birth defect worldwide, impacting roughly 1 in 100 live births, which equates to over 1.35 million infants annually. Congenital heart disease (CHD) includes a wide range of structural cardiac defects that arise during fetal development and endure throughout an individual's lifetime.

Aim: The Aim is to analyze the extensive spectrum of congenital heart disease (CHD), encompassing its structural, diagnostic, therapeutic, psychosocial, and global health dimensions, while highlighting the disparities between high-income and low and middle-income countries (LMICs).

Objectives:

1. To analyze the structural variations of congenital heart defects.
2. To review advancements in prenatal and postnatal diagnostic techniques, including fetal echocardiography and AI-assisted imaging.

AUTHOR'S AFFILIATION:

[1] Student, Department of Cardiovascular Technology, Sharda School of Allied Health Sciences, Sharda University, Greater Noida, Uttar Pradesh, India.

[2] Assistant Professor, Department of Medical Lab Technology, Sharda School of Allied Health Sciences, Sharda University, Greater Noida, Uttar Pradesh, India.

[3] Professor, Department of Biochemistry, Sharda School of Allied Health Sciences, Sharda University, Greater Noida, Uttar Pradesh, India.

[4] Associate Professor, Department of Biochemistry, Sharda School of Allied Health Sciences, Sharda University, Greater Noida, Uttar Pradesh, India.

CORRESPONDING AUTHOR:

Ajit Pal Singh, Assistant Professor, Department of Medical Lab Technology, Sharda School of Allied Health Sciences, Sharda University, Greater Noida, Uttar Pradesh, India.

E-mail: ajit.singh1@sharda.ac.in

➢ **Received:** 31-07-2025 ➢ **Accepted:** 25-08-2025

3. To evaluate evolving treatment modalities such as catheter-based interventions, minimally invasive and robotic surgeries, and novel regenerative therapies like tissue-engineered valves and stem cell treatments.
4. To highlight the lifelong psychological and developmental challenges faced by CHD patients and their families.
5. To assess global disparities in CHD outcomes and propose policy-driven strategies for equitable care.

Material: This study integrates multidisciplinary literature, real-world patient accounts, and global health data, bolstered by clinical insights from paediatric cardiology, surgery, imaging, psychology, and health policy domains.

Result: In affluent nations, more than 85% of infants diagnosed with congenital heart disease now reach maturity, attributable to advancements in identification and treatment. Nevertheless, low and middle-income countries encounter postponed diagnoses, restricted access to specialized healthcare, and elevated death rates due to infrastructural and institutional deficiencies. The data demonstrates a significant disparity in results that highlights the necessity for focused global actions.

Conclusion: Coronary heart disease continues to be a significant clinical and societal concern globally. Addressing the care gap necessitates synchronized global initiatives encompassing early screening, healthcare workforce enhancement, and the incorporation of patient-centered congenital heart disease services into national health frameworks. Advocating for health equity guarantees both survival and quality of life for all children born with congenital heart disease, irrespective of geographic or socioeconomic conditions.

KEYWORDS

• Heart• fetal• Infants• Diagnosis• Patients• Paediatric

INTRODUCTION

A. Definition of Congenital Heart Disease (CHD)

Congenital Heart Disease (CHD) involves heart or main blood artery abnormalities at birth. Embryonic cardiac development problems can affect the heart's walls, valves, arteries, and veins. Congenital heart disease (CHD) can range from minor heart wall holes to severe diseases like hypoplastic left heart syndrome or transposition of the major arteries. These defects can impede the heart's ability to pump blood, disturb oxygenation, and cause long-term health issues if left untreated. Some issues are asymptomatic or self-resolving, but others require medical monitoring, surgery, or catheterization. CHD is a chronic condition that manifests from infancy to maturity, requiring lifelong, specialized treatment.[1]



Figure 1: Heart

B. Significance of the Topic

As revealed by the 2023 Global Burden of Disease Study, congenital heart disease (CHD) is the most common birth defect worldwide, affecting approximately 1.35 million newborns

yearly. It causes one-third of congenital abnormality-related baby deaths. Coronary heart disease continues to be a global health issue, despite advancements in identification and treatment. More than 85% of children with congenital heart diseases (CHD) survive into adulthood in wealthy countries, but kids in low and middle-income countries (LMICs) are often diagnosed late, have limited access to surgeries, and have worse outcomes due to underfunded healthcare systems. The rising number of corrected or palliated adult congenital cardiac disease (ACHD) patients raises complex clinical, social, and healthcare policy issues. Congenital heart disease (CHD) affects physical health, neurodevelopment, emotional stability, and family relationships in addition to survival. The global economic and psychosocial impact on families and healthcare systems emphasizes the need to provide equal access to comprehensive congenital heart disease care and support.[2]

C. Objective of the Paper/Presentation

This research examines the complexity and diverse nature of congenital heart disease (CHD), a "hidden heart" issue for many. It integrates cardiology, genetics, public health, and patient experiences to explain CHD's biochemical, clinical, and emotional aspects. Recent developments in diagnostic imaging, surgical and catheter-based therapy, and customized medicine are discussed, along with global issues such as delayed diagnosis, health disparities, and the psychosocial impact of CHD. This exploration highlights that CHD is a lifelong journey through the voices of patients, families, and caregivers. The effort aims to inspire advocacy, awareness, and investment in research and equitable care to create a world where every child born with CHD survives and thrives. This research bridges science and humanity to highlight an illness that affects millions worldwide yet is often unseen.

THE ANATOMY OF A MALFORMATION

A. Types of Congenital Heart Disease (CHD)

CHD encompasses a broad range of structural cardiac anomalies present at birth, typically categorized by the presence or absence of cyanosis impaired oxygenation that causes a bluish skin tint. This classification helps guide early clinical management and urgency of intervention.

1. Acyanotic Defects

Acyanotic heart abnormalities induce left-to-right blood shunting, which initially does not affect systemic oxygenation but can lead to volume overload, pulmonary hypertension, and heart failure. Atrial septal defect (ASD), where oxygen-rich blood from the left atrium mixes with oxygen-poor blood in the right atrium; ventricular septal defect (VSD), the most common congenital heart defect worldwide, characterized by a hole between the ventricles that can range from small and asymptomatic to large and symptomatic; and patent ductus arteriosus (PDA), where the fetal ductus arteriosus fails to close after birth.

2. Cyanotic Defects

Right-to-left blood shunting allows oxygen-poor blood to flow into the systemic circulation, resulting in cyanosis in individuals with cyanotic heart defects. Since many illnesses are life-threatening, early surgery is needed. Tetralogy of Fallot (TOF) is a complex defect that involves a ventricular septal defect (VSD), pulmonary stenosis, right ventricular hypertrophy, and an overriding aorta; Transposition of the Great Arteries (TGA) is characterized by the reversal of the aorta and pulmonary artery, which creates parallel circulations that are incompatible with life without prompt medical or surgical correction; and Tricuspid Atresia is another congenital heart defect. These diseases demonstrate the structural intricacy of congenital cardiac disease and the necessity for fast, tailored diagnosis and treatment.

B. Fetal Heart Development

Congenital heart disease (CHD) can result from disruptions in the heart's development and function between the third and eighth weeks of gestation. Cardiovascular development begins with mesodermal cells forming a linear heart tube (days 15–21) and cardiac looping in the fourth week, which creates the early heart chambers. Septation splits the atria, ventricles, and outflow tracts between weeks four and eight, and endocardial cushions create the mitral and tricuspid valves, completing the heart. Malformations can originate from genetic, epigenetic, or environmental disruptions, with complicated CHDs often caused by aberrant neural crest cell migration that impairs septa and massive vessel formation. These developmental

roots explain why numerous abnormalities commonly co-occur and why CHD is often coupled with facial or skeletal deformities.

C. Etiological Factors

CHD is a complex illness caused by genetic predisposition and environmental factors, with over half of cases remaining idiopathic despite genetic analysis improvements. New genomic technologies like whole exome and genome sequencing have identified genetic contributors like Trisomy 21 (Down syndrome), linked to atrioventricular septal defects, and 22q11.2 deletion syndrome (DiGeorge syndrome), linked to conotruncal anomalies. Septal and valve abnormalities are also caused by single-gene mutations in NKX2-5, GATA4, TBX1, and NOTCH1, whereas copy number variations and de novo mutations cause sporadic or syndromic presentations. Poorly controlled maternal diabetes increases outflow tract anomalies, prenatal infections like rubella and cytomegalovirus, and teratogenic exposures like retinoic acid, alcohol, and antiepileptic drugs. Assisted reproductive technologies and advanced maternal age increase CHD risk. Epigenetic alterations and maternal-fetal immunological interactions affect cardiac gene expression during development, according to new research. CHD's various phenotypes and multiple causes require better diagnostic technologies, preventive methods, and individualized treatments.

THE DIAGNOSTIC JOURNEY

The diagnosis of congenital heart disease (CHD) is essential for assessing outcomes, especially for intricate anomalies that could be fatal if not detected promptly. Better prenatal imaging, genetic testing, and monitoring of new-borns have significantly increased the chances of finding congenital heart disease early, allowing for quick treatment and coordinated care for mothers and babies. Nonetheless, diagnostic difficulties persist, particularly in resource-limited environments and for lesions that appear late.

A. Prenatal Detection

1. Fetal Echocardiography

Fetal echocardiogram is the definitive method for the prenatal diagnosis of congenital heart disease, usually conducted between 18 and 24 weeks of gestation. This non-invasive imaging technique uses high-resolution ultrasonography to assess fetal cardiac architecture, rhythm, and function in utero.[11] Fetal echocardiography is especially recommended for high-risk pregnancies, including those with:

1. Abnormal obstetric ultrasound findings (e.g., increased nuchal translucency, hydrops)
2. Family history of CHD



Figure 2: Cardiopulmonary support system (Cardio help)

2. Role of Prenatal Genetic Testing

Prenatal genetic testing plays a crucial role in diagnosing congenital heart disease (CHD), with chromosomal microarray analysis (CMA) and next-generation sequencing (NGS) increasingly utilized to identify genetic causes when fetal heart abnormalities are detected. Common chromosomal abnormalities linked to CHD include trisomies 21, 18, and 13, as well as 22q11.2 deletions, often associated with conotruncal and atrioventricular septal defects. Non-invasive prenatal testing (NIPT) using cell-free fetal DNA has become a widely recommended routine screening method for detecting major aneuploidies. Additionally, advanced techniques such as whole exome and genome sequencing (WES/WGS) can identify pathogenic variants in cardiac-related genes like NKX2-5 and GATA4, particularly in syndromic cases. Combining detailed cardiac imaging with genomic data allows for comprehensive prenatal risk assessment, facilitating early multidisciplinary care planning and informed family counseling.

B. Postnatal Detection

1. Clinical Signs and Symptoms

During the neonatal era, congenital heart disease (CHD) may manifest with either modest or pronounced symptoms, contingent upon the type of abnormality. Critical congenital heart disease (CHD), which includes conditions like transposition of the great arteries and pulmonary atresia that rely on the ductus arteriosus, usually shows symptoms within the first few hours to days after birth.[12] Principal manifestations encompass:

1. Cyanosis (bluish skin, especially with crying or feeding)
2. Respiratory distress or rapid breathing
3. Poor feeding or failure to thrive
4. Weak peripheral pulses or differential blood pressure (e.g., in coarctation)
5. Heart murmur (although not always present in critical CHD)

Some defects, particularly acyanotic lesions like small VSDs, may remain asymptomatic and be detected incidentally or during routine pediatric exams.

2. Diagnostic Tools

Transthoracic echocardiography is the main method for diagnosing congenital heart disease (CHD) after birth by seeing cardiac structure and blood flow in real time. Cardiovascular MRI is useful for examining extra cardiac arteries, ventricular sizes, and function in older children and adults with complex CHD due to its detailed soft tissue contrast. Preoperative planning can benefit from cardiac CT angiographies thorough mapping of vascular anatomy in abnormal pulmonary venous return and aortic arch anomalies. While more invasive, cardiac catheterization is necessary for hemodynamic assessment and therapeutic operations such as balloon atrial septostomy and patent ductus arteriosus closure. These diagnostic methods assess heart structure, function, and dynamics to inform tailored treatment.

C. Role of New-born Screening

1. Pulse Oximetry Screening

Since its widespread use in the last decade, pulse oximetry screening has become a cost-effective and non-invasive method for detecting significant congenital heart disease (CHD). Within 24 to 48 hours postnatally, this evaluation measures oxygen saturation in the right hand (pre-ductal) and one foot (post-ductal). A saturation level below 95% or a difference over 3% between locations requires echocardiography. Research shows that pulse oximetry can detect up to 75% of significant congenital heart disease cases without audible murmurs or acute symptoms. In countries where this screening is routine, it has significantly reduced hospital discharge rates of undetected congenital heart disease patients and improved infant survival.[13]

2. Early Detection Protocols and Health System Integration

New-born screening for congenital heart disease (CHD) relies on quick follow-up, paediatric cardiology, good referral systems, and global protocol standardization, especially in low-and middle-income countries where diagnosis delays are common. New technologies use portable heart ultrasonography, remote heart ultrasound, and computer programs to increase screening accuracy, reduce false results, and make testing easier in remote places. From before birth to childhood, diagnosing congenital heart disease (CHD) is challenging and requires numerous processes. Early and precise diagnosis improves health outcomes, allows for timely treatment, and reduces long-term complications. Future imaging and genetic technology will be more precise, predictive, and accessible to detect congenital cardiac disease before it becomes life-threatening.[14]

LIVING WITH A CONGENITAL HEART DEFECT

Congenital heart disease (CHD) survivors are becoming common. Since surgery, heart operations, and long-term care have improved, over 85% of babies with congenital heart disease (CHD) now live to adulthood, resulting in a rapidly growing population of adults with CHD worldwide. Most patients need ongoing medical care, lifestyle changes, and psychosocial support to manage their condition's complex issues.

A. Treatment and Interventions

1. Medical Management

Acute and chronic congenital heart disease (CHD) treatment must be adjusted to the

defect, severity, heart failure, arrhythmias, pulmonary hypertension, age, and other health factors. Patients with prosthetic valves, Fontan circulation, or atrial arrhythmias receive anticoagulants to minimize thrombotic risk, while diuretics, ACE inhibitors, and beta-blockers treat heart failure symptoms. Sildenafil and bosentan are increasingly used to treat pulmonary arterial hypertension, especially in severe CHD cases like Eisenmenger syndrome. The goal of medical therapy is to improve heart function, prevent problems, and increase quality of life.



Figure 3: Chest pain (Myocardial infaction, blocked artery with hypoxia)

2. *Surgical Interventions: Corrective vs. Palliative*

Surgery has greatly improved congenital heart disease (CHD) survival, especially for complex abnormalities that were once fatal. Repairing ventricular septal defect (VSD) or transposition of the great arteries (TGA) with an arterial switch operation restores cardiac structure and function. In cases where full anatomical correction is not possible, palliative surgeries like Norwood, Glenn, and Fontan reroute blood flow and maximize oxygenation, but they require further revisions and pose long-term hazards. New neonatal and phased surgical methods, neuroprotective anesthesia, and postoperative intensive care have improved patient outcomes and lowered morbidity.

3. *Catheter-Based Techniques*

Congenital heart disease (CHD) treatment now relies on catheter-based methods, which are less intrusive than open-heart surgery and have lower risks, complications, and recovery times. Device closures for atrial septal defects (ASD), patent ductus arteriosus (PDA), and muscular ventricular septal defects (VSDs); balloon valvuloplasty and angioplasty for stenotic valves or vessels; and stent placement for coarctation of the aorta or pulmonary artery stenosis are common. High-risk individuals often undergo hybrid surgical-catheter treatments. Advances in 3D imaging, robotic navigation, and patient-specific implants expand and improve CHD interventional therapy.

B. Lifelong Monitoring and Care

1. *Transition from Pediatric to Adult Congenital Heart Disease (ACHD) Care*

The growing number of adults with congenital heart disease (CHD) has led to the specialized field of adult CHD, emphasizing the need for a structured transition from pediatric to adult care to ensure continuity and prevent lost follow-up, a common and potentially harmful issue. Transition programs, usually commencing between 12 and 14, help teens acquire self-management skills and emotionally prepare for adulthood. ACHD children need lifetime care in specialized centers with pediatric and adult cardiologists due to CHD's complicated anatomical and physiological aspects.

2. *Managing Long-Term Complications*

After undergoing correction, patients with congenital heart disease may experience long-term complications that depend on the specific defect and the type of treatment received. Examples of late problems include arrhythmias caused by surgical scar tissue and altered conduction pathways, heart failure particularly in patients with systemic right ventricles following Mustard or Senning repairs and endocarditis, which can persist for a lifetime and necessitates dental care and antibiotic prophylaxis. Thromboembolic events, ventricular dysfunction, and organ problems like hepatic or renal difficulties, especially in Fontan patients, necessitate lifelong multidisciplinary follow-up.

C. Psychosocial and Developmental Impacts

Perioperative hypoxia, frequent hospitalizations, and genetic abnormalities increase the risk of neurodevelopmental

delays, including learning disabilities, executive function deficits, and attention disorders, in complex or cyanotic congenital heart disease (CHD). Though supervised physical activity is recommended for health, many patients, especially those with persistent abnormalities or palliative repairs, may have restricted exercise tolerance. CHD impacts the whole family, putting emotional, financial, and logistical hardship on caregivers and siblings who may feel neglected or take on caring duties. Adolescence is a time when children and teenagers struggle with body image, social inclusion, and emotional well-being. Psychosocial resilience, supportive families, counseling, peer groups, and educational accommodations help individuals overcome these problems and live fulfilled lives. A lifelong, multidisciplinary strategy that emphasizes early intervention, tailored therapy, and comprehensive psychological support is critical to fostering development, integration, and quality of life as the CHD population ages.

Table 1: Showing the Impact of Congenital Heart Disease (CHD) on Families and Quality of Life, incorporating psychosocial, economic, emotional, and developmental dimensions

Domain	Specific Impact	Short-Term Effects	Long-Term Effects	Support Strategies
Emotional/ Psychological	Parental anxiety, depression, PTSD; stress around diagnosis, surgery, and prognosis	Acute emotional distress during diagnosis, surgery, ICU stays	Chronic stress, caregiver burnout, PTSD	Counseling, peer support groups, mental health services
Social/Family Dynamics	Strain on marital relationships, sibling neglect, disrupted routines	Disrupted family roles and social life	Altered family functioning, long-term sibling emotional needs	Family therapy, sibling support programs, community integration initiatives
Economic/ Financial	High out-of-pocket costs for travel, care, medications; lost income due to caregiving	Missed work, reduced income, emergency expenses	Long-term financial instability, difficulty securing employment	Financial aid programs, flexible employment policies, insurance navigation support
Educational/ Developmental	Developmental delays, frequent school absences, need for accommodations	Missed schooling due to hospital visits, fatigue, or recovery	Academic underperformance, social isolation	Individualized Education Plans (IEPs), tutoring, school-based CHD awareness
Child's Quality of Life	Physical limitations, emotional struggles, poor self-image (especially in adolescence)	Fatigue, limited participation in physical activities	Risk of social withdrawal, depression, reduced independence	Cardiac rehabilitation, psychosocial counseling, adaptive sports and peer programs
Healthcare Navigation	Complex care coordination, frequent appointments, information overload	Stress from managing multiple specialists and unfamiliar medical systems	Care fatigue, gaps in continuity of care as child ages	Patient navigators, transition programs to adult CHD care, caregiver education workshops
Cultural and Systemic Barriers	Stigma, lack of awareness in certain communities or regions, limited support systems	Delayed diagnosis or care-seeking due to stigma or misinformation	Isolation, underutilization of available resources	Community outreach, culturally sensitive education, multilingual support services

THE CUTTING EDGE: RESEARCH AND INNOVATION

The domain of congenital heart disease (CHD) care has undergone a transformation due to swift technological and scientific advancements, shifting from a focus on high-risk surgeries and symptom management to the forefront of precision diagnostics, minimally invasive techniques, and regenerative medicine. These advanced advances enhance survival rates and cardiac function and present the possibility of curative treatments and substantial improvements in the long-term quality of life for patients with CHD globally.[16]

A. Advances in Imaging and Diagnostics

1. 3D Echocardiography

Congenital heart disease (CHD) diagnosis and surgical planning have improved using three-dimensional echocardiography's comprehensive spatial reconstructions. It improves septal defect, valve morphology, and complex anatomies, such as the double outlet right ventricle and atrioventricular septal defect assessment. Real-time 3D imaging in intraoperative and interventional treatments improves catheter-based repair guiding, making it a vital CHD management tool.

2. Fetal MRI

Fetal cardiac MRI has become a valuable complement to echocardiography, especially when acoustic windows are limited or when clearer imaging of extracardiac structures like the pulmonary veins and aortic arch is needed. Advances in motion-corrected fetal MRI techniques now enable detailed visualization of the fetal heart without sedation, enhancing early and accurate diagnosis of congenital heart disease (CHD). This technology is particularly effective for identifying vascular rings, heterotaxy syndromes, and complex pulmonary venous anomalies, expanding diagnostic capabilities in fetal cardiology.

3. AI-Assisted Interpretation

AI is boosting congenital heart disease (CHD) diagnosis by speeding up, improving, and standardizing picture interpretation. A deep learning method can automatically detect septal anomalies, valve abnormalities, and chamber sizes in prenatal and pediatric echocardiograms. AI-powered decision support systems let clinicians spot minor irregularities, stratify risk, and forecast post-surgical outcomes using historical data. As echocardiographic software integrates AI technologies, clinical decision-making and telemedicine access to specialized care in disadvantaged locations will increase.

B. Surgical and Technological Innovations

1. Minimally Invasive Surgeries

Minimally invasive cardiac surgery (MICS) using small incisions and video-assisted techniques is increasingly used in pediatric and adult congenital heart disease (CHD) patients to reduce postoperative pain, hospital stays, and recovery time. This method reduces infection risks and improves cosmetic outcomes, which are crucial for children and adolescents. Atrial septal defect closures, valve repairs, and coarctation repairs are common. MICS is becoming more accessible as surgical equipment and training improve, despite its technical challenges.

2. 3D-Printed Heart Models

One of the most transformative advances in surgical planning for congenital heart disease is the use of patient-specific 3D-printed heart models, created from imaging data such as MRI, CT, or 3D echocardiography, allowing surgeons to physically explore complex cardiac anatomy prior to surgery. These models have been shown to improve surgical accuracy, reduce operative time, and enhance informed consent by helping families better understand the planned procedures. Beyond surgery, 3D printing is also valuable in education and simulation training, enabling medical teams and trainees to rehearse challenging procedures in a realistic, hands-on way before performing them on patients.

3. Robotic and Image-Guided Assistance

Congenital cardiac surgery is increasingly incorporating robotic systems to enhance precision in valve repairs and minimally invasive reoperations, offering improved dexterity and visibility in confined spaces. When combined with augmented reality overlays that provide real-time imaging feedback during surgery, these technologies represent the future of personalized, image-guided treatment for congenital heart disease (CHD). Although still not widely adopted, these advanced instruments are paving the way for more precise and individualized surgical care.

C. Genetic and Stem Cell Research

1. Personalized Medicine Approaches

Whole genome sequencing and polygenic risk scoring are ushering in precision medicine for congenital heart disease (CHD), where genetic testing can identify patients at risk for arrhythmias, heart failure, and syndromic complications. Pharmacogenomics allows genetically personalized drug regimens, improving efficacy and reducing side effects. Genotype-phenotype relationships in thousands of CHD cases are being mapped to enable pregnancy prevention and personalized management.

2. *Regenerative Therapies and Tissue-Engineered Patches*

In cardiac tissue engineering, stem cells and decellularized scaffolds are used to create bioengineered patches and valves that can grow with the patient, potentially reducing the need for multiple surgeries to treat congenital heart disease (CHD). In complex cases like single ventricle physiology, induced pluripotent stem cells (iPSCs) are being tested for cardiac tissue repair. Boston Children's Hospital, Stanford, and the European Congenital Heart Tissue Consortium are developing 3D-bioprinted cardiac tissues that could become living heart structures. These advances could transform CHD treatment from resolving problems to replacing heart tissue. Along with high-resolution imaging, AI-based diagnostics, and robotic surgery, these technologies are expanding personalized, minimally invasive, and potentially curative treatments. We must invest in translational research, ethical clinical trials, and equitable global access to ensure that innovative CHD care is available to patients worldwide, not just in top institutions.[17]

PUBLIC HEALTH, POLICY AND AWARENESS

Congenital heart disease (CHD) diagnosis and treatment have improved, yet global inequities remain. High-income countries have more children with congenital heart disease (CHD) surviving and thriving, while low-income countries may have delayed diagnoses, limited access to specialized care, and unnecessary deaths. To provide quick, high-quality care for all children with congenital heart disease worldwide, healthcare institutions, policymakers, and communities must work together.[18]

A. Global Disparities in CHD Care

Globally, congenital heart disease (CHD) is the leading cause of neonatal and infant death, with considerable differences between high-and low-income countries. According to the World Health Organization and the 2023 Global Burden of Disease survey, more than 70% of children born with congenital heart disease (CHD) live in low and middle-income countries (LMICs), while fewer than 10% receive surgical or interventional therapy. Pediatric cardiac surgery, echocardiography, and basic newborn screening are scarce in sub-Saharan Africa, Southeast Asia, and parts of Latin America. Many countries lack qualified pediatric cardiologists, cardiac anesthesiologists, and intensive care teams, causing delays, misdiagnoses, and unnecessary deaths before children receive treatment. The "CHD care gap" includes medical and structural issues such as healthcare infrastructure, finance, staff development, and political commitment. Global initiatives like the Global Initiative for Children's Surgery and the World Heart Federation's CHD working group assess needs, improve local training, and promote fair surgical care.[19]

B. Role of Advocacy Groups and NGOs

Through awareness, support, and treatment availability, NGOs, advocacy groups, and patient-led networks help close congenital heart disease (CHD) care gaps. Patient support networks like the Children's Heart Foundation, Mended Little Hearts, and Little Hearts Matter empower families and reduce stigma with peer support, educational resources, and assistance. By organizing surgical trips, connecting patients with international doctors, and facilitating telehealth, local NGOs often improve public health systems. The U.S. Congenital Heart Futures Reauthorization Act (2020) shows that advocacy groups modified laws and funding to require new-born pulse oximetry screening, insurance coverage for congenital heart disease treatment, and increased research funding. International groups like Save a Child's Heart, Children's Heart Link, and the International Children's Heart Foundation improve surgical capacity, educate local healthcare teams, and treat underserved areas. These initiatives demonstrate the importance of lobbying in altering health regulations, gaining financing, and raising awareness that congenital heart disease (CHD) is a chronic condition that requires continuing care.

C. The Importance of Early Detection and Education

1. Community Awareness Campaigns

Early detection of congenital heart disease (CHD) is crucial for improving outcomes, but it relies heavily on public awareness and access to timely screening. Many new-borns with CHD may appear healthy at birth, and without universal screening, critical defects can go undetected until they become life-threatening. To address this, public health campaigns

around the world have focused on educating parents, birth attendants, and frontline healthcare providers about early warning signs such as cyanosis, feeding difficulties, respiratory distress, and poor weight gain. Initiatives like "Know the Signs, save a Life" and "Hearts for Hearts" have played a key role in increasing early recognition and referrals across both rural and urban communities.

2. Integration into Maternal and Child Health Programs

Integrating congenital heart disease (CHD) screening into standard maternal and child health services constitutes a very sustainable approach for early identification. Global health organizations are increasingly recommending that fetal echocardiography and pulse oximetry be included in national care guidelines for pregnant women and new mothers, and it's important to train midwives and community health workers to perform screenings and spot warning signs, especially in places without specialist care. Both WHO and UNICEF support adding congenital heart disease (CHD) monitoring and treatment to maternity, neonatal, and child health (MNCH) programs, along with important actions like vaccination and nutrition. Integrating education with accessible screening elevates early detection from a mere clinical instrument to a vital lifeline. Addressing the global disparity in CHD care necessitates synchronized public health policy, lobbying, and investment in sustainable, community-based solutions. Collective global action, early detection, and equitable care can transform congenital heart disease from a silent killer into a treatable and survivable illness for children worldwide, therefore fulfilling the commitment to "unveil the mysteries" of this ailment.[20]

HUMANIZING THE CONDITION: REAL STORIES

Congenital heart disease (CHD) is frequently characterized by statistics, anatomical illustrations, and surgical guidelines. However, beyond the facts exists a deeply human experience one influenced by fear, resilience, sacrifice, and remarkable strength. Stories from people with congenital heart disease (CHD), their families, and the doctors who treat them help explain the science behind the condition, giving a better understanding of how it affects lives and what it's like to live with a heart that is not normally formed.

A. Patient Narratives

Stories of Resilience and Triumph:

Children and adults with congenital heart disease (CHD) are redefining what it means to flourish with a chronic condition worldwide, overcoming repeated surgeries, physical limits, and lifelong uncertainty. Emma, an 8-year-old with hypoplastic left heart syndrome, dances competitively after three open-heart surgeries, demonstrating how medical improvements and family support can lead to a full, active life. Luis, 29, from rural Guatemala, is a nurse and champion for early CHD screening in impoverished regions after a visiting medical mission repaired his undiagnosed ventricular septal defect (VSD) at age 12. Sarah, 38, a Fontan circulation patient, leads Adult Congenital Heart Association training and lobbying on adult CHD issues like fatigue and arrhythmias. These stories show how human strength, community support, and accessible treatment form a CHD journey beyond medicine.

B. Parental and Caregiver Perspectives

1. Emotional and Psychological Journey

Parents typically experience vigilance, optimism, and despair once their child is diagnosed with congenital heart disease (CHD). Prenatal diagnosis can help parents connect with support networks and coordinate care, but uncertainty, especially in the first year or while awaiting procedures, is emotionally draining. Caregivers often experience worry, anxiety, and sadness, especially in situations of severe CHD or frequent hospitalizations. Siblings may feel emotionally displaced or take on caring tasks at a young age.

2. Financial and Social Challenges

The financial and social burdens of raising a child with congenital heart disease (CHD) are frequently substantial and persistent, especially in nations with public healthcare systems. Families encounter many expenses, such as pharmaceuticals, transportation to specialized medical facilities, missed wages owing to caregiving duties, and expenses associated with postoperative rehabilitation. Parents often encounter insurance obstacles, battle for

their child's educational modifications, and balance employment with demanding caring responsibilities. Despite these challenges, numerous caregivers demonstrate exceptional resilience, which research indicates is significantly enhanced by early access to psychosocial support, continuous medical treatment, and the backing of strong peer networks.

C. Healthcare Provider Insights

1. The Multidisciplinary Team Behind CHD Care

Paediatric and adult cardiologists, cardiothoracic surgeons, intensivists, anaesthesiologists, nurses, genetic counsellors, social workers, physical and occupational therapists, and mental health professionals work together to treat congenital heart disease (CHD). Each team member brings unique skills and perspectives to deliver comprehensive treatment and develop lifelong relationships with patients and their families.

2. Personal Reflections from Providers

Paediatric cardiologists observe parents' worry during fetal echocardiograms and see children's excitement when they take their first steps after protracted ICU stays. Surgeons contemplate the exquisite precision needed to correct microscopic flaws and the profound responsibility of holding a child's heart in their hands, while cardiac unit nurses are often called "second parents," providing compassionate advice through medical treatment. Providers attain healing, success, and meaningful connection despite emotional strain, burnout, and moral problems, especially in resource-limited or unpredictable contexts. These stories show that CHD care is founded in anatomy and humanity, showcasing resilience, sensitivity, and hope via community. We learn more about CHD beyond clinical bounds and appreciate this ongoing journey by accepting these personal perspectives.

CONCLUSION

Advances in prenatal and postnatal diagnostics, such as 3D echocardiography and AI-assisted imaging, have improved early detection and treatment planning for congenital heart disease (CHD), which affects 1 in 100 live births worldwide. New therapies like minimally invasive surgeries and regenerative medicine offer hope for better outcomes, but CHD is also about patients' resilience, families' emotional and financial struggles, and multidisciplinary healthcare teams' compassion. These advances have not eliminated global gaps in access to timely diagnosis and specialist care. We must raise awareness of CHD indicators and early screening, fund research into advanced medicines and public health policies, support affected families holistically, and push for equal healthcare infrastructure internationally. Genetics, stem cells, and digital health advances promise individualized, regenerative treatments powered by worldwide collaboration and inclusivity. Innovation, empathy, and equity can ensure that every child born with CHD, regardless of geography or socioeconomic status, receives the care and support they need to thrive, unlocking the mysteries of the hidden heart and changing congenital heart disease.

REFERENCES

1. Moro, C., Iudici, A., & Turchi, G. P. (2025). Parents of Children with Congenital Heart Disease (CHD): A Narrative Study of the Social and Clinical Impact of CHD Diagnosis on Their Role and Health. Behavioral Sciences, 15(3), 269.
2. Haq, I. U., Husnain, G., Ghadi, Y. Y., Innab, N., Alajmi, M., & Aljuaid, H. (2025). Enhancing pediatric congenital heart disease detection using customized 1d cnn algorithm and phonocardiogram signals. Heliyon, 11(3).
3. Peña-Martínez, E. G. (2025). Global Evaluation of Congenital Heart Disease-Associated Non-Coding Variants (Doctoral dissertation, University of Puerto Rico, Rio Piedras (Puerto Rico)).
4. Zhang, Q., Lai, S., Zhang, Y., Ye, X., Wu, Y., Lin, T., ... & Yan, J. (2023). Associations of elevated glucose levels at each time point during OGTT with fetal congenital heart diseases: a cohort study of 72,236 births. BMC pregnancy and childbirth, 23(1), 837.
5. Khera, R., Asnani, A. H., Krive, J., Addison, D., Zhu, H., Vasbinder, A., ... & Okwuosa, T. M. (2025). Artificial intelligence to enhance precision medicine in cardio-oncology: a scientific statement from the American

Heart Association. Circulation: Genomic and Precision Medicine, 18(2), e000097.

6. Makhaddin, G. I., & Atakishiyeva, V. N. (2025). Inflammatory Heart Disease in Patients with Rheumatological. Inflammatory Myocardial Diseases, 3.
7. Gasimova, F. N., Babayeva, G. H., Nur-Mammadova, G. S., Babayeva, L. K., Makhaddin, G. I., Atakishiyeva, V. N., ... & Niftiyev, P. G. (2025). Inflammatory Heart Disease in Patients with Rheumatological Profile. In Inflammatory Myocardial Diseases. IntechOpen.
8. Fan, S., & Hu, Y. (2022). Integrative analyses of biomarkers and pathways for heart failure. BMC Medical Genomics, 15(1), 72.
9. Ji, Y., Zhang, X., Tang, H., Luo, H., Zhao, S., Qiu, Z., ... & Diao, L. (2019, September). Education platform of congenital heart disease based on mixed reality technology. In International Conference of Pioneering Computer Scientists, Engineers and Educators (pp. 313-334). Singapore: Springer Singapore.
10. Kim, D. S. (2016). A computational pipeline for identifying copy number variation from single nucleotide polymorphism data and applications to congenital heart disease (Doctoral dissertation).
11. Soni, T., Gupta, D., Uppal, M., Juneja, S., Gulzar, Y., & Ghafoor, K. Z. (2024). Deep neural network framework for predicting cardiovascular diseases from ECG signals. Recent Advances in Computer Science and Communications.
12. Liu, Y., & Wang, B. (2025). Advanced applications in chronic disease monitoring using IoT mobile sensing device data, machine learning algorithms and frame theory: a systematic review. Frontiers in Public Health, 13, 1510456.
13. Sooriamoorthy, D., Malarvili, M. B., Anas, A., & Meste, O. (2025). Emerging Technologies and Concepts for Cardiovascular Risk Detection.
14. Liu, G., Zhang, Z., Zhang, J., & Gao, H. (2025). Non-coding RNAs: targets for. Reviews in Cardiovascular Pharmacology: 2023.
15. Zhang, X., Liu, Z., Guo, B., Cui, Q., Gao, J., Kang, Z., & Xiao, G. (2024). Pharmacological Mechanisms of Periplocae Cortex Against Congestive Heart Failure Based on Network Pharmacology and Experimental Evaluation. Natural Product Communications, 19(3), 1934578X241229289.
16. Verghese, G. R., Clarke-Myers, K., & Anderson, J. B. (2023). Quality and Value Improvement in Pediatric Cardiac Care: The World of Quality Improvement. In Pediatric Cardiology: Fetal, Pediatric, and Adult Congenital Heart Diseases (pp. 1-39). Cham: Springer International Publishing.
17. Arsalan, M. H., Mubin, O., Al Mahmud, A., Khan, I. A., & Hassan, A. J. (2025, April). Mapping Data-Driven Research Impact Science: The Role of Machine Learning and Artificial Intelligence. In Metrics (Vol. 2, No. 2, p. 5). MDPI.
18. Wu, Z., Cai, R., Wu, S., Zhu, G., Cui, S., Yu, Q., ... & Zhou, Y. (2022). The Meridian–Viscera Correlationship: Theory and Mechanisms of Heart Meridian–Heart–Brain Interactions. In Advanced Acupuncture Research: From Bench to Bedside (pp. 311-344). Cham: Springer International Publishing.
19. He, B., Kwan, A. C., Cho, J. H., Yuan, N., Pollick, C., Shiota, T., ... & Ouyang, D. (2023). Blinded, randomized trial of sonographer versus AI cardiac function assessment. Nature, 616(7957), 520-524.
20. Ouyang, D., He, B., Ghorbani, A., Yuan, N., Ebinger, J., Langlotz, C. P., ... & Zou, J. Y. (2020). Video-based AI for beat-to-beat assessment of cardiac function. Nature, 580(7802), 252-256.